EA200501023A1 - Терапевтические составы для лечения болезней, связанных с наличием бета-амилоида - Google Patents

Терапевтические составы для лечения болезней, связанных с наличием бета-амилоида

Info

Publication number
EA200501023A1
EA200501023A1 EA200501023A EA200501023A EA200501023A1 EA 200501023 A1 EA200501023 A1 EA 200501023A1 EA 200501023 A EA200501023 A EA 200501023A EA 200501023 A EA200501023 A EA 200501023A EA 200501023 A1 EA200501023 A1 EA 200501023A1
Authority
EA
Eurasian Patent Office
Prior art keywords
agent
treatment
diseases associated
beta amyloid
amyloid
Prior art date
Application number
EA200501023A
Other languages
English (en)
Other versions
EA012325B1 (ru
Inventor
Франсин Жерве
Франческо Беллини
Original Assignee
Ньюрочем (Интернэшнл) Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ньюрочем (Интернэшнл) Лимитед filed Critical Ньюрочем (Интернэшнл) Лимитед
Publication of EA200501023A1 publication Critical patent/EA200501023A1/ru
Publication of EA012325B1 publication Critical patent/EA012325B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

Данное изобретение относится к способам и фармацевтическим композициям для лечения заболеваний, связанных с β-амилоидом, включая болезнь Альцгеймера. Изобретение, например, включает способ сопутствующей терапии для лечения субъекта, заключающийся во введении субъекту эффективного количества первого агента и второго агента, отличающийся тем, что указанный первый агент лечит амилоидное β-заболевание, нейродегенерацию или клеточную токсичность; а указанный второй агент представляет собой лекарственное вещество или пищевую добавку.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200501023A 2002-12-24 2003-12-24 Терапевтические составы для лечения болезней, связанных с наличием бета-амилоида EA012325B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43637902P 2002-12-24 2002-12-24
US48221403P 2003-06-23 2003-06-23
PCT/CA2003/002011 WO2004058258A1 (en) 2002-12-24 2003-12-24 Therapeutic formulations for the treatment of beta-amyloid related diseases

Publications (2)

Publication Number Publication Date
EA200501023A1 true EA200501023A1 (ru) 2005-12-29
EA012325B1 EA012325B1 (ru) 2009-08-28

Family

ID=32685452

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200501023A EA012325B1 (ru) 2002-12-24 2003-12-24 Терапевтические составы для лечения болезней, связанных с наличием бета-амилоида

Country Status (13)

Country Link
US (1) US20060135403A1 (ru)
EP (2) EP1585520A1 (ru)
JP (2) JP2006512417A (ru)
KR (1) KR20050101537A (ru)
AU (2) AU2003292936A1 (ru)
BR (1) BR0317747A (ru)
CA (2) CA2511606A1 (ru)
EA (1) EA012325B1 (ru)
IL (1) IL169338A0 (ru)
MX (1) MXPA05006940A (ru)
NO (1) NO20053077L (ru)
NZ (1) NZ541282A (ru)
WO (2) WO2004058258A1 (ru)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2695607C2 (ru) * 2014-05-09 2019-07-24 Текнимеди Сосьедади Текнику-Медисинал С.А. (r)-пирлиндол и его фармацевтически приемлемые соли для применения в медицине
RU2695647C2 (ru) * 2014-05-09 2019-07-25 Текнимеди Сосьедади Текнику-Медисинал С.А. (s)-пирлиндол и его фармацевтически приемлемые соли для применения в медицине

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
DK1628663T3 (da) 2003-05-15 2010-03-08 Roskamp Res Llc Fremgangsmåde til fremstilling af medikamenter til reduktion af amyloid-aflejring, amyloid-neurotoksicitet og mikrogliose
US20070010573A1 (en) 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US20050142191A1 (en) * 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
JP2007516938A (ja) * 2003-06-23 2007-06-28 ニューロケム （インターナショナル） リミテッド アミロイド関連疾患を治療するための方法および組成物
AU2004251511A1 (en) * 2003-06-23 2005-01-06 Neurochem (International) Limited Treatment of protein aggregation disorders
AU2011250847B2 (en) * 2003-06-23 2013-06-20 Bhi Limited Partnership Methods and compositions for treating amyloid-related diseases
ES2754221T3 (es) * 2003-08-29 2020-04-16 Ono Pharmaceutical Co Compuesto capaz de unirse al receptor de S1P y uso farmacéutico del mismo
SG149039A1 (en) * 2003-12-17 2009-01-29 Elan Pharm Inc Ass IMMUNOGENIC PEPTIDE CARRIER CONJUGATES AND METHODS OF PRODUCING SAME
MXPA06011969A (es) * 2004-04-14 2006-12-15 Warner Lambert Co Combinacion terapeutica para tratamiento de la enfermedad de alzheimer.
JP2008504372A (ja) * 2004-06-18 2008-02-14 ニューロケム （インターナショナル） リミティッド β−アミロイド関連疾患の治療のための治療用製剤
JP4717537B2 (ja) * 2004-08-31 2011-07-06 株式会社 資生堂 皮膚外用組成物
BRPI0517790A (pt) * 2004-11-12 2008-10-21 Neurochem Int Ltd métodos e composições fluoradas para tratar doenças relacionadas à amilóide
US8044100B2 (en) * 2004-12-22 2011-10-25 Bellus Health Inc. Methods and compositions for treating amyloid-related diseases
TW200716088A (en) * 2005-04-15 2007-05-01 Neurochem Int Ltd Formulations and methods for treating amyloidosis
US7420071B2 (en) * 2005-05-04 2008-09-02 Uchicago Argonne, Llc Thermally stable surfactants and compositions and methods of use thereof
KR20080090408A (ko) 2005-11-30 2008-10-08 아보트 러보러터리즈 항-Ａβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법
DK1976877T4 (en) 2005-11-30 2017-01-16 Abbvie Inc Monoclonal antibodies to amyloid beta protein and uses thereof
BRPI0619747B8 (pt) 2005-12-12 2021-05-25 Ac Immune Sa método para produzir uma composição de vacina terapêutica, construto antigênico, composição de vacina, usos de um construto antigênico, e, método para preparar e produzir um medicamento para o tratamento de uma condição ou doença associada com amilóide
RU2551782C2 (ru) 2005-12-12 2015-05-27 Ац Иммуне Са Специфические в отношении амилоида бета (а бета) 1-42 моноклональные антитела, обладающие терапевтическими свойствами
CA2634871A1 (en) 2005-12-22 2007-11-08 Neurochem (International) Limited Treatment of renal disorders, diabetic nephopathy and dyslipidemias
JP2009523175A (ja) * 2006-01-10 2009-06-18 パイペックス，インコーポレイテッド 目標とされる安定な銅状態を達成及び維持して銅関連中枢神経系疾患を予防及び治療するための医薬組成物及び方法
PL2046833T3 (pl) 2006-07-14 2014-01-31 Ac Immune Sa Humanizowane przeciwciało przeciw amyloidowi beta
LT2468770T (lt) 2006-07-14 2018-05-25 Ac Immune S.A. Humanizuotas antikūnas prieš beta amiloidą
FI3851447T3 (fi) 2006-10-12 2023-11-15 Bellus Health Inc Menetelmiä, yhdisteitä, koostumuksia ja vehikkeleitä 3-amino-1-propaanisulfonihapon vapauttamiseksi
US8188046B2 (en) 2006-10-16 2012-05-29 University Of South Florida Amyloid beta peptides and methods of use
SG173409A1 (en) 2006-11-24 2011-08-29 Ac Immune Sa N-(methyl)-1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimers
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
GB0701970D0 (en) * 2007-02-01 2007-03-14 Wilson Stuart Treatment of protein aggregation diseases
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
WO2008106657A2 (en) * 2007-03-01 2008-09-04 Intezyne Technologies, Inc. Encapsulated amyloid-beta peptides
EP2160352A2 (en) * 2007-05-24 2010-03-10 Simone Arca Method for the production of binary clathrate hydrates of hydrogen
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
KR20150055103A (ko) 2007-06-12 2015-05-20 에이씨 이뮨 에스.에이. 아밀로이드 베타에 대해 인간화된 항체
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
KR101600095B1 (ko) 2007-06-12 2016-03-07 에이씨 이뮨 에스.에이. 모노클로널 항 베타 아밀로이드 항체
US8501695B2 (en) 2007-07-20 2013-08-06 Diamedica, Inc. Tissue kallikrein for the treatment of diseases associated with amyloid protein
EP2044951A1 (en) 2007-10-02 2009-04-08 Merz Pharma GmbH & Co. KGaA The use of substances for the treatment of loss of eyesight in humans with glaucoma and other degenerative eye diseases
US9403902B2 (en) 2007-10-05 2016-08-02 Ac Immune S.A. Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody
CA2701620C (en) 2007-10-05 2014-12-09 Alzheimer's Institute Of America, Inc. Method for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis with (-)-nilvadipine enantiomer
CA2701790A1 (en) 2007-10-05 2009-04-16 Ac Immune S.A. Use of humanized anti-beta-amyloid antibody in ocular diseases
WO2009059239A2 (en) * 2007-11-02 2009-05-07 Mayo Foundation For Medical Education And Research REDUCING Aβ42 LEVELS AND Aβ AGGREGATION
EP2149380A1 (en) * 2008-07-29 2010-02-03 Medivet Pharma, S.L. Veterinary immunotherapy compositions for the Aged Related Cognitive Dysfunction.
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
WO2010042603A1 (en) * 2008-10-08 2010-04-15 Cingulate Neuro Therapeutics, Llc Amyloid and depression
SI2408807T1 (sl) 2009-03-18 2021-11-30 Ac Immune Sa Postopek za terapevtsko uporabo
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
JP5051274B2 (ja) * 2009-06-04 2012-10-17 住友化学株式会社 加硫ゴムが有する粘弾性特性を改善させるためのｓ−（３−アミノプロピル）チオ硫酸および／またはその金属塩の使用
EP2311823A1 (en) 2009-10-15 2011-04-20 AC Immune S.A. 2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases
JP2013523182A (ja) 2010-04-15 2013-06-17 アボット・ラボラトリーズ アミロイドベータ結合タンパク質
US20110256064A1 (en) 2010-04-16 2011-10-20 Ac Immune, S.A. Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-like Proteins
DK2558446T5 (da) 2010-04-16 2019-12-09 Ac Immune Sa Nye forbindelser til behandling af sygdomme associerede med amyloid- eller amyloidlignende proteiner
JP6081356B2 (ja) 2010-07-30 2017-02-15 エーシー イミューン エス．エー． 安全で機能的なヒト化抗βアミロイド抗体
CN105348387B (zh) 2010-08-14 2020-08-25 Abbvie 公司 β淀粉样蛋白结合蛋白
MY164376A (en) 2010-10-07 2017-12-15 Univ Leuven Kath Phosphospecific antibodies recognizing tau
WO2012055933A1 (en) 2010-10-26 2012-05-03 Ac Immune S.A. Liposome-based construct comprising a peptide modified through hydrophobic moieties
US20120328605A1 (en) * 2010-10-27 2012-12-27 Daniel Larocque Compositions and uses
EA201691399A1 (ru) 2011-01-10 2016-10-31 Зинфандел Фармасьютикалз, Инк. Способы и готовые лекарственные формы для лечения болезни альцгеймера
WO2013009799A1 (en) * 2011-07-11 2013-01-17 Beth Israel Deaconess Medical Center, Inc. Vitamin d receptor agonists and uses thereof
KR20160099732A (ko) 2011-09-23 2016-08-22 에이씨 이뮨 에스.에이. 백신 요법
AR092779A1 (es) 2011-10-07 2015-05-06 Ac Immune Sa Composicon farmaceutica que comprende anticuerpos que se unen a conformeros de proteinas tau
CA2869438C (en) 2012-04-05 2021-08-17 Ac Immune S.A. Humanized tau antibody
US20130315891A1 (en) 2012-05-25 2013-11-28 Matthew Charles Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
SI2854841T1 (sl) 2012-06-04 2017-06-30 Diamedica Inc. Glikozilacijske izooblike humanega tkivnega kalikreina-1
CA2881464C (en) * 2012-08-07 2021-12-21 Children's Medical Center Corporation Potassium channel openers for treating neurodegenerative diseases
GEP201706739B (en) * 2012-12-13 2017-09-25 H Lundbeck As Compositions comprising vortioxetine and donepezil
US9200068B2 (en) * 2012-12-18 2015-12-01 Regents Of The University Of Minnesota Compositions and methods related to tauopathy
JP6568514B2 (ja) 2013-03-15 2019-08-28 エーシー イミューン エス．エー． 抗タウ抗体及び使用方法
WO2015110263A1 (en) 2014-01-21 2015-07-30 Ac Immune Sa Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyolid-like proteins
US10314911B2 (en) * 2014-04-08 2019-06-11 Healthpartners Research & Education Methods for protecting and treating traumatic brain injury, concussion and brain inflammation with intranasal insulin
WO2016079597A1 (en) 2014-11-19 2016-05-26 Axon Neuroscience Se Humanized tau antibodies in alzheimer's disease
JP6793134B2 (ja) 2015-06-05 2020-12-02 ジェネンテック， インコーポレイテッド 抗ｔａｕ抗体及び使用方法
MX2018001592A (es) 2015-08-10 2018-08-21 Alzheon Inc Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos.
KR20180085736A (ko) 2015-11-09 2018-07-27 더 유니버시티 오브 브리티쉬 콜롬비아 아밀로이드 베타 중간-영역 내 에피토프 및 이에 대해 구조적으로 선택성인 항체
CN108350051A (zh) 2015-11-09 2018-07-31 英属哥伦比亚大学 淀粉样蛋白β中的N-末端表位及其构象选择性抗体
WO2017079835A1 (en) 2015-11-09 2017-05-18 The University Of British Columbia Amyloid beta epitopes and antibodies thereto
ITUA20161679A1 (it) 2016-03-15 2017-09-15 Neuraxpharm Italy S P A Composizione per prevenire e trattare patologie neurodegenerative e disturbi cognitivi
US11970521B2 (en) 2016-08-20 2024-04-30 Arizona Board Of Regents On Behalf Of The University Of Arizona Neuroprotective beta amyloid core peptides and peptidomimetic derivatives
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
AR110321A1 (es) 2016-12-07 2019-03-20 Genentech Inc Anticuerpos antitau y métodos de uso
JP2020511937A (ja) 2016-12-07 2020-04-23 ジェネンテック， インコーポレイテッド 抗ｔａｕ抗体及び使用方法
US11857608B2 (en) 2017-03-09 2024-01-02 Diamedica Inc. Dosage forms of tissue kallikrein 1
JP2020515543A (ja) 2017-03-28 2020-05-28 ジェネンテック， インコーポレイテッド 神経変性疾患の治療方法
US11723945B2 (en) 2017-04-25 2023-08-15 Temple Otorongo Llc Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions
KR101917128B1 (ko) 2017-04-28 2018-11-09 강원대학교산학협력단 산양삼 추출물을 포함하는 알츠하이머병의 예방 또는 치료용 약학 조성물
WO2019018445A1 (en) * 2017-07-17 2019-01-24 Maxwell Biosciences, Inc. POLYTHERAPY MODULATING THE MODULATION OF CATHELICIDINE GENE EXPRESSION FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER DISEASES
US20200330592A1 (en) * 2017-10-09 2020-10-22 Keith Black Compositions and methods of treating alzheimer's and other amyloid related diseases
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US11124552B2 (en) 2017-10-25 2021-09-21 Ac Immune Sa Compositions of phosphorylated tau peptides and uses thereof
CN111757882B (zh) 2018-01-05 2023-08-22 Ac免疫有限公司 用于治疗、减轻或预防与Tau聚集体相关的病症的化合物
MX2020009991A (es) 2018-03-28 2020-10-14 Axon Neuroscience Se Metodos basados en anticuerpos para detectar y tratar la enfermedad de alzheimer.
MX2020013115A (es) 2018-06-04 2021-05-12 Ac Immune Sa Compuestos de tetrahidrobenzofuro[2,3-c]piridina y beta-carbolina para el tratamiento, el alivio o la prevencion de trastornos asociados con los agregados de tau.
CN112313230B (zh) 2018-06-04 2024-03-15 Ac免疫有限公司 用于治疗、缓解或预防与Tau聚集体相关的病症的新型化合物
KR20200086198A (ko) 2019-01-08 2020-07-16 주식회사 솔고 바이오메디칼 수소 흡장 금속을 포함하는 치매 예방 또는 치료용 조성물
WO2020150423A1 (en) * 2019-01-16 2020-07-23 Yumanity Therapeutics, Inc. Methods for the treatment of neurological disorders
CA3131805C (en) 2019-03-01 2023-11-21 Ac Immune Sa Novel compounds for the treatment, alleviation or prevention of disorders associated with tau aggregates
AU2020259406A1 (en) 2019-04-17 2021-11-04 Compass Pathfinder Limited Treatment of depression and other various disorders with psilocybin
JP7327788B2 (ja) * 2019-08-06 2023-08-16 学校法人福岡大学 糖化産物生成抑制剤及び医薬組成物
ES2821599A1 (es) 2019-10-24 2021-04-26 Univ Del Pais Vasco / Euskal Herriko Unibertsitatea Compuestos y metodos para el tratamiento de la enfermedad de alzheimer
CN112939823A (zh) * 2019-12-10 2021-06-11 中国石油天然气股份有限公司 泥页岩抑制剂制备方法及抑制剂的应用
KR20210133603A (ko) 2020-04-29 2021-11-08 정지영 굼벵이를 포함하는 치매 예방 또는 치료용 조성물
US20210353566A1 (en) * 2020-05-12 2021-11-18 Massachusetts Institute Of Technology The use of choline supplementation as therapy for apoe4-related disorders
AR123730A1 (es) 2020-10-15 2023-01-04 Ac Immune Sa Compuestos novedosos
IL310382A (en) 2021-08-27 2024-03-01 Genentech Inc Methods for treating tau pathologies
CN115624555A (zh) * 2022-02-24 2023-01-20 中国药科大学 猪去氧胆酸在制备抗抑郁药物中的应用
WO2023178049A1 (en) 2022-03-14 2023-09-21 Genentech, Inc. Predicting neurodegenerative diseases based on speech analyses
KR20230147988A (ko) * 2022-04-15 2023-10-24 아주대학교산학협력단 Rage 길항제 및 age 소거제를 포함하는 당뇨성 뇌졸중 예방 또는 치료용 약학적 조성물
WO2023250326A1 (en) 2022-06-21 2023-12-28 Genentech, Inc. Detecting longitudinal progression of alzheimer's disease (ad) based on speech analyses

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69434571T2 (de) * 1993-03-29 2006-08-03 Queen's University At Kingston, Kingston Propan-1,3-disulphonsäure und deren pharmazeutisch akzeptable Salze zur Behandlung von Amyloidosis
US5840294A (en) * 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
EP0866805A1 (en) * 1995-12-12 1998-09-30 Karolinska Innovations AB PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)
JPH10259126A (ja) * 1997-01-17 1998-09-29 Takeda Chem Ind Ltd アルツハイマー病治療・予防剤
ES2392391T3 (es) * 1998-02-11 2012-12-10 Bhi Limited Partnership Método para modular la activación de macrófagos
GB9805561D0 (en) * 1998-03-16 1998-05-13 Merck Sharp & Dohme A combination of therapeutic agents
JP2002515429A (ja) * 1998-05-15 2002-05-28 ネウロケム、インク ニューロン細胞死を調節する方法
RU2260599C2 (ru) * 1999-03-04 2005-09-20 Прикис Фамэсьютикэлс Инкопэрейтид МОДУЛЯТОР АГРЕГАЦИИ ПЕПТИДА β-АМИЛОИДА ДЛЯ ИНГИБИРОВАНИЯ АГРЕГАЦИИ ПЕПТИДОВ ПРИРОДНОГО β -АМИЛОИДА ИЛИ ДЛЯ ЛЕЧЕНИЯ СУБЪЕКТА ОТ НАРУШЕНИЯ, АССОЦИИРОВАННОГО С β -АМИЛОИДОЗОМ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ДЕТЕКЦИИ В БИОЛОГИЧЕСКОМ ОБРАЗЦЕ ПЕПТИДОВ ПРИРОДНОГО β -АМИЛОИДА
IL146143A0 (en) * 1999-04-28 2002-07-25 Univ Kingston Compositions and methods for treating amyloidosis
IL146009A0 (en) * 1999-05-05 2002-07-25 Neurochem Inc Stereoselective antifibrillogenic peptides and peptidomimetics thereof
US20020094335A1 (en) * 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
WO2001085093A2 (en) * 1999-12-23 2001-11-15 Neurochem, Inc. Compounds and methods for modulating cerebral amyloid angiopathy
US20020151591A1 (en) * 2000-10-17 2002-10-17 Anabella Villalobos Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders
WO2002036614A2 (en) * 2000-11-01 2002-05-10 Insight Biotechnology Limited Peptides for use in the treatment of alzheimer's disease
US20050031651A1 (en) * 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
US20050142191A1 (en) * 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
US20050038000A1 (en) * 2003-06-23 2005-02-17 Xianqi Kong Methods and compositions for the treatment of amyloid-and epileptogenesis-associated diseases
US7253306B2 (en) * 2003-06-23 2007-08-07 Neurochem (International) Limited Pharmaceutical drug candidates and methods for preparation thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2695607C2 (ru) * 2014-05-09 2019-07-24 Текнимеди Сосьедади Текнику-Медисинал С.А. (r)-пирлиндол и его фармацевтически приемлемые соли для применения в медицине
RU2695647C2 (ru) * 2014-05-09 2019-07-25 Текнимеди Сосьедади Текнику-Медисинал С.А. (s)-пирлиндол и его фармацевтически приемлемые соли для применения в медицине

Also Published As

Publication number Publication date
US20060135403A1 (en) 2006-06-22
NO20053077L (no) 2005-09-22
EP1581203A1 (en) 2005-10-05
NO20053077D0 (no) 2005-06-23
CA2511606A1 (en) 2004-07-15
WO2004058239A1 (en) 2004-07-15
JP2006525226A (ja) 2006-11-09
AU2003291910B2 (en) 2009-10-01
CA2511599A1 (en) 2004-07-15
AU2003291910A1 (en) 2004-07-22
AU2003292936A1 (en) 2004-07-22
EA012325B1 (ru) 2009-08-28
MXPA05006940A (es) 2006-02-22
IL169338A0 (en) 2007-07-04
BR0317747A (pt) 2005-11-22
JP2006512417A (ja) 2006-04-13
EP1585520A1 (en) 2005-10-19
KR20050101537A (ko) 2005-10-24
WO2004058258A1 (en) 2004-07-15
NZ541282A (en) 2009-02-28

Similar Documents

Publication Publication Date Title
EA200501023A1 (ru) Терапевтические составы для лечения болезней, связанных с наличием бета-амилоида
WO2007049098A3 (en) Therapeutic formulations for the treatment of beta-amyloid related diseases
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
EA200401473A1 (ru) Предотвращение и лечение амилоидогенного заболевания
DE60036456D1 (de) Antimikrobiell wirksames oder endotoxin neutralisierendes polypeptid
ES2187575T3 (es) Hexapeptidos ciclicos dotados de actividad antibiotica.
ATE432289T1 (de) Glp-1 und behandlungsmethode für diabetes
ATE515265T1 (de) Vitamin d und dessen analoge zur behandlung vom tumoren und anderen hyperproliferativen erkrankungen
DE69815122T2 (de) Saccharid-enthaltende zubereitungen zur behandlung von alzheimerschen erkrankung und von weiteren amyloidosen
DE60227658D1 (de) Verfahren zur behandlung neurodegenerativer, psychiatrischer und anderer störungen mit deacetylaseinhibitoren
EA200400135A1 (ru) Применение производных амидинов для лечения амилоидоза
DE59907752D1 (de) Verwendung von erythropoietin oder erythropoietin-derivaten zur behandlung von cerebralen ischämien
CY1110078T1 (el) Παρασκευασματα με ιωδιουχο ποβιδονη για την αγωγη τραυματων
ATE412646T1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
ATE409028T1 (de) Arzneien zur behandlung von nervenerkrankungen
DE60018409D1 (de) Verwendung von antiseptika zur herstelllung von arzneimitteln zur prophylaxe und behandlung von infektionen und/ oder funktionellen gewebeumformungen im körperinneren
RU2002129355A (ru) Применение фульвестранта при лечении резистентного рака молочной железы
WO2002076381A3 (en) Proanthocyanidins for the treatment of amyloid and alpha-synuclein diseases
PT1237562E (pt) Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas
EA200401295A1 (ru) Статиновая терапия для усиления поддержания когнитивной функции
EE200200549A (et) Jagatud doosi teraapia veresooni kahjustava aktiivsusega
EA202193190A1 (ru) Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов
DE69307702D1 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU